Oscar Health, INC

Oscar Health, Inc. announced the results of its 2026 Annual Meeting of Stockholders, confirming the election of eight director nominees and the approval of executive compensation and auditor ratification.

Oscar Health will participate in a fireside chat at the Goldman Sachs Global Healthcare Conference on June 8, 2026, to provide a business update and reaffirm its full-year 2026 guidance.

Oscar Health, Inc. has amended the employment agreement for Mario Schlosser, transitioning him from President of Technology and CTO to Co-Founder & Advisor to the CEO, effective June 1, 2026.

Oscar Health announced robust first-quarter 2026 financial results, showcasing significant year-over-year improvements and reaffirming its full-year guidance.

Oscar Health reaffirms its full-year 2026 financial guidance and announces a change in Board leadership, with Siddhartha Sankaran appointed as the new Independent Chair.

Oscar Health, Inc. announced its participation in the 2026 Raymond James Institutional Investors Conference, where it will reaffirm its full-year 2026 guidance.

Oscar Health, Inc. reported a significantly wider net loss in the third quarter of 2025 despite substantial revenue and membership growth, driven by increased medical expenses and risk adjustment transfers.

Oscar Health, Inc. reported a significant net loss in Q2 2025 despite strong revenue and membership growth, driven by increased medical expenses and risk adjustment transfers.

Oscar Health's Q1 2025 results show significant revenue growth and profitability, driven by a substantial increase in membership.

Oscar Health's Q3 2024 results show significant membership growth and improved financial metrics, despite a net loss for the quarter.

Oscar Health's Q2 2024 results show significant revenue growth and improved profitability, driven by a substantial increase in membership and better management of medical costs.

Oscar Health's first quarter of 2024 saw a significant increase in revenue and a return to profitability, driven by membership growth and improved cost management.

Oscar Health, Inc. reported a net loss of $443.2 million for 2025, reversing its 2024 profitability, driven by increased medical expenses and risk adjustment transfers, despite significant membership growth.

Oscar Health reports its first profitable year with a net income of $26.1 million and Adjusted EBITDA of $199.2 million for the year ended December 31, 2024, driven by membership growth and strategic initiatives.

Oscar Health, Inc. has issued restricted stock unit grant notices under its 2021 Incentive Award Plan, outlining terms for both retirement-eligible and non-retirement-eligible participants.

William Gassen, a Director of Oscar Health, Inc., received 684 shares of common stock on July 9, 2026.

Sid Sankaran, a Director of Oscar Health, Inc., received 858 shares of common stock on July 9, 2026.

David Plouffe, a Director of Oscar Health, Inc., received 681 shares of common stock on July 9, 2026.

Oscar Health Director Mario Schlosser executed a Rule 10b5-1 trading plan, resulting in the sale of a significant number of Class A common stock shares.

Oscar Health CEO Mark Bertolini sold a significant number of Class A common stock shares to cover tax obligations related to vested performance stock units, executing a pre-planned Rule 10b5-1 transaction.

Oscar Health CEO Mark Bertolini sold company stock to cover tax obligations related to vested stock units, executing a pre-planned Rule 10b5-1 trading plan.

Oscar Health, Inc. has announced its 2026 Annual Meeting of Stockholders will be held virtually on June 4, 2026, to elect directors, approve executive compensation, and ratify auditor appointment.

Oscar Health, Inc. has filed a definitive proxy statement with the SEC.

Oscar Health will hold its 2025 Annual Meeting of Stockholders virtually on June 4, 2025, to vote on director elections, ratification of the accounting firm, and executive compensation.

Oscar Health, Inc. has filed a definitive proxy statement with the SEC.

Oscar Health has filed its proxy statement for the 2024 Annual Meeting of Stockholders, detailing proposals for director elections, auditor ratification, and executive compensation approval.

The Vanguard Group filed an amended Schedule 13G, reporting 0% beneficial ownership in Oscar Health Inc. following an internal realignment.

Dragoneer Investment Group, along with Marc Stad, filed an amended Schedule 13G disclosing beneficial ownership of 0.3% of Oscar Health, Inc.'s Class A Common Stock.

T. Rowe Price Investment Management, Inc. has reported an amended beneficial ownership of 3.7% in Oscar Health Inc. Class A common stock.

Deerfield Mgmt, L.P. and affiliated entities report 0% beneficial ownership in Oscar Health, Inc. Class A Common Stock.

JPMorgan Chase & Co. has updated its passive ownership stake in Oscar Health, Inc., reporting a 4.5% beneficial ownership of Class A Common Stock.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 6.4% passive beneficial ownership stake in Oscar Health, Inc. as of June 30, 2025.